遗传决定的循环细胞因子水平与卒中风险
本研究采用两样本孟德尔随机化方法,利用8293名健康成人的全基因组关联研究数据构建41种细胞因子和生长因子的遗传工具,在MEGASTROKE数据集中评估其与卒中及亚型的关联,并以UK Biobank作为独立验证样本。结果显示,遗传决定的单核细胞趋化蛋白-1(MCP-1/CCL2)水平升高与任何卒中、缺血性卒中、大动脉卒中及心源性栓塞性卒中风险升高相关,但与心房颤动无关。
要点
- 遗传决定的MCP-1水平升高与任何卒中及缺血性卒中风险升高相关。
- MCP-1水平升高与大动脉卒中和心源性栓塞性卒中关联最明显。
- MCP-1与冠心病和心肌梗死也呈关联,但与心房颤动无关。
核心结论
- 遗传决定的循环MCP-1水平升高与卒中风险升高相关,尤其与大动脉卒中和心源性栓塞性卒中相关。
- 针对MCP-1或其受体能否降低卒中发生率尚需进一步研究。
研究设计与样本
- 两样本孟德尔随机化研究:遗传工具来自8293名健康成人的全基因组关联研究,共41种细胞因子和生长因子。
- 在MEGASTROKE全基因组关联研究数据集中评估(67 162例病例;454 450例对照),采用逆方差加权meta分析、加权中位数分析、MR-Egger回归和多变量孟德尔随机化。
- 以UK Biobank队列作为独立验证样本(4985例病例;364 434例对照)。
主要发现
- 遗传易感的高MCP-1水平与任何卒中风险升高相关(每1 SD增加的OR为1.06;95%CI 1.02-1.09;P=0.0009)。
- 与任何缺血性卒中相关(OR 1.06;95%CI 1.02-1.10;P=0.002),与大动脉卒中相关(OR 1.19;95%CI 1.09-1.30;P=0.0002),与心源性栓塞性卒中相关(OR 1.14;95%CI 1.06-1.23;P=0.0004)。
- 与小血管卒中或脑出血无显著关联;敏感性分析结果稳定,校正心血管危险因素后仍显著。
- UK Biobank验证:任何卒中OR 1.08(95%CI 0.99-1.17;P=0.09),任何缺血性卒中OR 1.07(95%CI 0.97-1.18;P=0.17)。
- 遗传决定的高MCP-1水平与冠状动脉疾病相关(OR 1.04;95%CI 1.00-1.08;P=0.04),与心肌梗死相关(OR 1.05;95%CI 1.01-1.09;P=0.02),与心房颤动无关联。
关键数值与推荐
- 观察性研究meta分析显示卒中患者循环MCP-1水平高于对照。
- MCP-1遗传工具与卒中亚型的关联采用逆方差加权meta分析、加权中位数分析、MR-Egger回归和多变量孟德尔随机化评估。
临床怎么用
- MCP-1可能作为卒中风险相关的炎症标志物,尤其在大动脉卒中和心源性栓塞性卒中方面。
- 目前尚不支持将靶向MCP-1或其受体用于降低卒中发生率,需进一步研究。
局限性
- UK Biobank中任何卒中与任何缺血性卒中的关联未达统计学显著(P=0.09和P=0.17)。
- 靶向MCP-1或其受体能否降低卒中发生率尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytokines and growth factors have been implicated in the initiation and propagation of vascular disease. Observational studies have shown associations of their circulating levels with stroke. Our objective was to explore whether genetically determined circulating levels of cytokines and growth factors are associated with stroke and its etiologic subtypes by conducting a 2-sample Mendelian randomization (MR) study. METHODS: Genetic instruments for 41 cytokines and growth factors were obtained from a genome-wide association study of 8293 healthy adults. Their associations with stroke and stroke subtypes were evaluated in the MEGASTROKE genome-wide association study data set (67 162 cases; 454 450 controls) applying inverse variance-weighted meta-analysis, weighted-median analysis, Mendelian randomization-Egger regression, and multivariable Mendelian randomization. The UK Biobank cohort was used as an independent validation sample (4985 cases; 364 434 controls). Genetic instruments for monocyte chemoattractant protein-1 (MCP-1/CCL2) were further tested for association with etiologically related vascular traits by using publicly available genome-wide association study data. RESULTS: Genetic predisposition to higher MCP-1 levels was associated with higher risk of any stroke (odds ratio [OR] per 1 SD increase, 1.06; 95% CI, 1.02-1.09; P=0.0009), any ischemic stroke (OR, 1.06; 95% CI, 1.02-1.10; P=0.002), large-artery stroke (OR, 1.19; 95% CI, 1.09-1.30; P=0.0002), and cardioembolic stroke (OR, 1.14; 95% CI, 1.06-1.23; P=0.0004), but not with small-vessel stroke or intracerebral hemorrhage. The results were stable in sensitivity analyses and remained significant after adjustment for cardiovascular risk factors. Analyses in the UK Biobank showed similar associations for available phenotypes (any stroke: OR, 1.08; 95% CI, 0.99-1.17; P=0.09; any ischemic stroke: OR, 1.07; 95% CI, 0.97-1.18; P=0.17). Genetically determined higher MCP-1 levels were further associated with coronary artery disease (OR, 1.04; 95% CI, 1.00-1.08; P=0.04) and myocardial infarction (OR, 1.05; 95% CI, 1.01-1.09; P=0.02), but not with atrial fibrillation. A meta-analysis of observational studies showed higher circulating MCP-1 levels in patients with stroke in comparison with controls. CONCLUSIONS: Genetic predisposition to elevated circulating levels of MCP-1 is associated with higher risk of stroke, in particular with large-artery stroke and cardioembolic stroke. Whether targeting MCP-1 or its receptors can lower stroke incidence requires further study.
引用
- Georgakis MK, Gill D, Rannikmäe K, et al. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. Circulation. 2019. PMID: 30586705. doi:10.1161/CIRCULATIONAHA.118.035905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。